spacer
home > ebr > winter 2003 > the future of biomanufacturing
PUBLICATIONS
European Biopharmaceutical Review

The Future of Biomanufacturing

In my previous article, I reviewed the recent history of biopharmaceutical manufacturing, and the factors that have driven the industry to be the size and shape that it is today. In this article, I will be looking at the emerging trends and technologies, and considering the influence that they will have on biopharmaceutical manufacturing in the future.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Sharon Grimster, Director of Westerly Projects Ltd

Sharon Grimster started her career working on clinical trials at Guys Hospital Medical School in London. She then moved to Celltech, working in research for four years prior to taking up various management positions within contract manufacturing. Sharon subsequently managed preclinical and clinical development programmes for both new chemical entities and biological entities. Following the mergers with Chiroscience and Medeva, Sharon became Head of Biologics Manufacturing Development. She left Celltech in 2002 and is now a Director of Westerly Projects Ltd, a consultancy company offering development services to the biopharmaceutical industry globally.

spacer
Sharon Grimster
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement